Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

ORILISSA (elagolix) for the Treatment of Pain Associated with Endometriosis

Drug Name

ORILISSA™ (elagolix)

Developer

AbbVie and Neurocrine Biosciences

Therapy Class

Gonadotropin-releasing hormone (GnRH) antagonist

Current Indication

Moderate to severe pain associated with endometriosis

Market Sector

Obstetrics and gynaecology

Development Status

Approved in the US
Expand

Go Top